A Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination With Ipilimumab for the Treatment of Patients With Advanced Hypermutated Solid Tumors Detected by a Blood Based Assay
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2019
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms NIMBLe
- 17 Oct 2018 Status changed from not yet recruiting to recruiting.
- 20 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Sep 2018.
- 11 Jun 2018 Planned initiation date changed from 1 Mar 2018 to 1 Jul 2018.